These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19557166)

  • 1. Pandemic vaccine preparedness--have we left something behind?
    Capua I; Kajaste-Rudnitski A; Bertoli E; Vicenzi E
    PLoS Pathog; 2009 Jun; 5(6):e1000482. PubMed ID: 19557166
    [No Abstract]   [Full Text] [Related]  

  • 2. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.
    Wkly Epidemiol Rec; 2015 Mar; 90(12):109-20. PubMed ID: 25796641
    [No Abstract]   [Full Text] [Related]  

  • 3. Zoonotic influenza viruses: antigenic and genetic characteristics and development of candidate vaccine viruses for pandemic preparedness.
    Wkly Epidemiol Rec; 2016 Mar; 91(11):133-43. PubMed ID: 26995804
    [No Abstract]   [Full Text] [Related]  

  • 4. Zoonotic influenza viruses: antigenic and genetic characteristics and development of candidate vaccine viruses for pandemic preparedness.
    Wkly Epidemiol Rec; 2017 Mar; 92(12):129-44. PubMed ID: 28337863
    [No Abstract]   [Full Text] [Related]  

  • 5. Recommended composition of influenza virus vaccines for use in the 2015–2016 northern hemisphere influenza season.
    Wkly Epidemiol Rec; 2015 Mar; 90(11):97-108. PubMed ID: 25771542
    [No Abstract]   [Full Text] [Related]  

  • 6. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.
    Wkly Epidemiol Rec; 2014 Oct; 89(42):457-64. PubMed ID: 25337626
    [No Abstract]   [Full Text] [Related]  

  • 7. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.
    Wkly Epidemiol Rec; 2018 Mar; 93(12):142-52. PubMed ID: 29569430
    [No Abstract]   [Full Text] [Related]  

  • 8. Recommended composition of influenza virus vaccines for use in the 2017 southern hemisphere influenza season.
    Wkly Epidemiol Rec; 2016 Oct; 91(41):469-84. PubMed ID: 27758094
    [No Abstract]   [Full Text] [Related]  

  • 9. Vaccine production: potential engineering approaches to pandemic influenza.
    Harding CV; Heuer AH
    J Pharm Sci; 2007 Nov; 96(11):2879-85. PubMed ID: 17721947
    [No Abstract]   [Full Text] [Related]  

  • 10. Zoonotic influenza viruses: antigenic and genetic characteristics and development of candidate vaccine viruses for pandemic preparedness.
    Wkly Epidemiol Rec; 2016 Oct; 91(42):485-99. PubMed ID: 27766828
    [No Abstract]   [Full Text] [Related]  

  • 11. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.
    Wkly Epidemiol Rec; 2011 Oct; 86(43):469-80. PubMed ID: 22046595
    [No Abstract]   [Full Text] [Related]  

  • 12. Vaccinate for the next H2N2 pandemic now.
    Nabel GJ; Wei CJ; Ledgerwood JE
    Nature; 2011 Mar; 471(7337):157-8. PubMed ID: 21390107
    [No Abstract]   [Full Text] [Related]  

  • 13. Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season.
    Wkly Epidemiol Rec; 2018 Mar; 93(12):133-41. PubMed ID: 29569429
    [No Abstract]   [Full Text] [Related]  

  • 14. Recommended composition of influenza virus vaccines for use in the 2014 southern hemisphere influenza season.
    Wkly Epidemiol Rec; 2013 Oct; 88(41):437-48. PubMed ID: 24159667
    [No Abstract]   [Full Text] [Related]  

  • 15. Concomitant administration of seasonal trivalent and pandemic monovalent H1N1 live attenuated influenza vaccines.
    Woo JC; Ambrose CS
    Influenza Other Respir Viruses; 2009 Nov; 3(6):257-9. PubMed ID: 19903206
    [No Abstract]   [Full Text] [Related]  

  • 16. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statement on influenza vaccination for the 2007-2008 season. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2007 Jul; 33(ACS-7):1-38. PubMed ID: 17663034
    [No Abstract]   [Full Text] [Related]  

  • 18. [The 50% effective dose (ED50a) of seasonal spilt influenza vaccine in mice].
    Huang BY; Wang XP; Tang WJ; Wang WL; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Apr; 25(2):92-5. PubMed ID: 21863626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommended composition of influenza virus vaccines for use in the 2013–2014 northern hemisphere influenza season.
    Wkly Epidemiol Rec; 2013 Mar; 88(10):101-14. PubMed ID: 23544236
    [No Abstract]   [Full Text] [Related]  

  • 20. WHO recommendations on the composition of the 2013/14 influenza virus vaccines in the northern hemisphere.
    Eurosurveillance editorial team
    Euro Surveill; 2013 Feb; 18(9):. PubMed ID: 23470023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.